title: The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain.
authors.affiliation: AstraZeneca, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Sánchez-Covisa
authors.affiliation: AstraZeneca, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Capel
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: R
authors.initials: R
authors.lastname: Schmidt
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Charokopou
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: B G
authors.initials: BG
authors.lastname: Verheggen